2001 OTA E-Posters
(Click here to view a complete list of
2001 OTA Annual Meeting Poster Abstracts)
Key:
* =
something of value received
^ =
FDA statement
< = presentation was funded by an OTA administered grant
Note: Presentations are PDF files and require Adobe® Acrobat® Reader to open. To install the Adobe® Acrobat® Reader software on your computer free-of-charge, please click here: Adobe® Acrobat® Reader.
Disclaimer
The material presented at the OTA Annual Meetings has been made available by the Orthopaedic Trauma Association for educational purposes only. The material is not intended to represent the only, nor necessarily best, method or procedure appropriate for the medical situations discussed, but rather is intended to present an approach, view, statement or opinion of the faculty which may be helpful to others who face similar situations.
The OTA disclaims any and all liability for injury or other damages resulting to any individual attending the annual meeting and for all claims which may arise out of the use of the techniques demonstrated therein by such individuals whether these claims shall be asserted by physician or any other person.
Disclosure
The names of authors presenting the papers on the Scientific Program are printed in boldface.
The paper presenter was responsible for querying the co-authors regarding the disclosure of their work. Paper authors whose presentations have a * by the title have indicated they or their co-authors (department) received something of value (in excess of $500) from a commercial company or institution which relates directly or indirectly to the subject of their presentation. The OTA does not intend this identification to decrease the value of the presentation or to imply bias. It is intended solely for information.
To follow ACCME guidelines the OTA/AAOS has identified the options to disclose as follows:
a. Research or institutional support has been received;
b. Miscellaneous non-income support (e.g., equipment or services), commercially derived honoraria, or other non-research related funding (e.g., paid travel);
c. Royalties;
d. Stock or Stock options; or
e. Consultant or employee.
In indication of the participant's disclosure appears after his or her name as well as the commercial company or institution that provided support.
FDA Statement
All drugs and medical devices used in the United States are administered in accordance with Food and Drug Administration (FDA) regulations. These regulations vary depending on the risks associated with the drug or medical device, the similarity of the drug or medical device to products already on the market, and the quality and scope of clinical data available.
Some drugs or medical devices demonstrated at the Annual Meeting have not been cleared by the FDA or have been cleared by the FDA for specific purposes only. The FDA has stated that it is the responsibiltiy of the physician to determine the FDA clearance status of each drug or medical device he or she wishes to use in clinical practice.
OTA policy provides that "off label" uses of drug or medical device may be described in the OTA's CME activities so long as the "off label" use of the drug or medical device is also specifically disclosed (i.e., it must be disclosed that the FDA has not cleared the drug or device for the described purpose). Any drug or medical device is being used "off label" if the described use is not set forth on the product's approved label.
